Active Filter(s):
Details:
Akelos's oral lead compound AKE-1018, at 10-times the lowest effective antihyperalgesic dose tested, does not affect heart rate, blood pressure, motor strength/coordination, is non-sedating, and lacks the potential for abuse.
Lead Product(s): AKE-1018
Therapeutic Area: Neurology Product Name: AKE-1018
Highest Development Status: Preclinical Product Type: Undisclosed
Partner/Sponsor/Collaborator: Weill Cornell Medicine
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 04, 2021